Data provided by Nasdaq. Minimum 15 minutes delayed.
Aerpio Pharmaceuticals Completes Patient Enrollment in TIME-2b Study, a Phase 2b Clinical Trial of Lead Candidate AKB-9778 in Patients with Diabetic Retinopathy
Aerpio Pharmaceuticals Announces Inducement Grants
Aerpio Pharmaceuticals Announces Appointment of Michael Rogers as Chief Financial Officer
|There are currently no events scheduled.|